MENA

Three regional dynamics stand out in MENA this quarter. First, the region’s visible psychedelic activity is being channelled through ketamine and esketamine, not classical psychedelics. Israel is the strongest example: Ministry of Health material says esketamine is approved by the Ministry and available in hospitals and specialised clinics, which makes it the region’s clearest regulated access route for a psychedelic-adjacent medicine. The UAE shows a similar pattern, with MoHAP materials discussing esketamine as a licensed option for treatment-resistant depression, again through a specialist medical framework rather than open prescribing. Egypt and Iran reinforce this same theme from the research side, with Blossom’s country context pointing to ketamine-led, depression-focused clinical and publication activity in Cairo, Tehran, Zanjan, Shiraz and other university-linked settings. The regional signal is therefore not a broad move towards psilocybin or MDMA access, but a cautious expansion of controlled anaesthetic-derived therapies in psychiatric practice.

Second, MENA’s only clearly visible classical-psychedelic research cluster sits in Israel, and it is still tightly research-bounded. Blossom tracks one Israeli psilocybin trial on the national register, focused on PTSD, and Israel’s broader research profile also includes MDMA-assisted therapy and translational mechanism work. That matters regionally because it is a rare example of an institutionally mature ecosystem producing classical-psychedelic evidence inside a highly controlled legal environment. By contrast, the rest of the region shows either no linked trials in Blossom, or no public evidence of a comparable trial cluster. Algeria, Morocco, Tunisia, Libya, Iraq, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Sudan, Yemen, Bahrain and Palestine currently present as low-signal or placeholder pages in Blossom, which itself is meaningful: there is no sign of a distributed MENA research wave comparable to what is visible in parts of Europe or Latin America.

Third, the policy texture across MENA is one of medical-only exception-making, not harmonisation. Israel’s Ministry of Health pages make the access rules around psychiatric treatment explicit, and the UAE’s regulatory material similarly points to controlled medical use under specialist governance. In Egypt, the legal framework remains strongly prohibitive outside authorised medical or scientific use, while Jordan’s scheduling and import guidance continues to frame psychotropics as controlled substances. Iran also remains restrictive for general access, despite a small academic ketamine footprint. These country-level signals matter at the regional level because they suggest that even where clinical interest exists, access is mediated by drug-control law, import permissions, hospital formulary decisions and ethics review, rather than any shared MENA-wide reform agenda.

A fourth, softer dynamic is the gulf between clinical capability and public visibility. Several systems in the region clearly have psychiatry, anaesthesia and research infrastructure capable of hosting ketamine or esketamine work, yet only a few publish that activity in ways that Blossom can currently link. Egypt’s university and hospital ecosystem is a good example, as is Jordan’s clinician-led ketamine familiarity. This creates a regional asymmetry: capability may exist in more places than the public record shows, but the visible research and access footprint is concentrated in Israel and, to a lesser degree, the UAE and Egypt. For researchers and investors, that means the region should not be read as uniformly closed, but as highly selective, with the strongest signals clustered in systems that can combine controlled-substance compliance, specialist psychiatry and formal clinical governance.

Over the next 12 to 24 months, the MENA region is more likely to see incremental clinical and regulatory clarification than sweeping reform. Israel should remain the key source of new evidence, particularly in PTSD, treatment-resistant depression, and supervised ketamine or esketamine implementation. Its current combination of Ministry-backed access, specialist clinics and a live trial pipeline gives it the best chance of producing publishable outcomes and practical care models that other countries in the region may watch closely, even if they do not copy them quickly.

The UAE is the next most plausible site for careful expansion, but likely only within tightly defined specialist settings. Public MoHAP material already distinguishes esketamine as a regulated treatment option, which suggests that further operationalisation, rather than policy liberalisation, is the more likely direction. Egypt and Jordan may continue to contribute small, clinician-led studies and hospital experience around ketamine, particularly where depression and perioperative psychiatry overlap, but public evidence still points to controlled medical use rather than a broader psychedelic policy shift.

For classical psychedelics, the outlook is slower. Israel is the only country in Blossom’s current MENA view with a clearly visible psilocybin trial, and even there the pathway remains research-bound. In the rest of the region, legal frameworks remain restrictive or opaque, and Blossom currently sees no sign of a region-wide regulatory opening. The most realistic near-term change is therefore a modest increase in local research literacy, more formal hospital governance around ketamine-derived treatments, and occasional trial launches in institutions with strong ethics and import systems. A regional policy wave looks unlikely in the short term.